Fischbach R
Br J Clin Pharmacol. 1983;16 Suppl 1(Suppl 1):167S-171S. doi: 10.1111/j.1365-2125.1983.tb02290.x.
In a double-blind parallel study in which a placebo phase preceded and followed the double-blind verum phase, midazolam 15 mg and Vesparax (150 mg secobarbital, 50 mg brallobarbital, 50 mg hydroxyzine) were administered to 30 female patients aged 20-76 years, suffering from insomnia secondary to neuromuscular disease. Both products were shown to be efficient hypnotics maintaining a constant level of effect. Midazolam proved to be better tolerated and, in contrast to Vesparax, did not cause hangover, nor did rebound phenomena ensue after its withdrawal.
在一项双盲平行研究中，在双盲真药阶段前后各有一个安慰剂阶段，对30名年龄在20 - 76岁、患有神经肌肉疾病继发失眠的女性患者给予15毫克咪达唑仑和Vesparax（150毫克司可巴比妥、50毫克溴异戊巴比妥、50毫克羟嗪）。两种产品均显示为有效的催眠药，效果维持恒定水平。事实证明，咪达唑仑的耐受性更好，与Vesparax不同，它不会引起宿醉，停药后也不会出现反跳现象。
